Phospho-AKT(Thr308) Antibody (YA5837)
(Synonyms: AKT)
Based on 1 Customer Validation
Phospho-AKT(Thr308) Antibody (YA5837) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT(Thr308).
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, ICC/IF, IP, ELISA
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
IP
IP: Immunoprecipitation
|
|---|---|---|---|---|
| Dilution Ratio | 1:1000-1:5000 | 1:200-1:1000 | 1:5000-1:20000 | 1:50-1:200 |
Product Details
Phospho-AKT(Thr308) Antibody (YA5837) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-AKT(Thr308).
-
Host Rabbit
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 60 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 60 kDa
Protein A
Non-conjugated
Phosphorylated
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
Akt/PKB (Protein kinase B), a serine/threonine protein kinase with antiapoptotic activity, is one of the major downstream targets of PtdIns (3, 4, 5) P3 signaling pathway. It contains a pleckstrin homology domain (PH domain) that specifically binds PtdIns (3, 4, 5) P3 on the plasma membrane. Akt phosphorylation and activation are directly determined by the level of PtdIns (3, 4, 5) P3 on the plasma membrane, which is regulated by PI3K. Akt consists of three isoforms: PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3. Akt isoforms have an N-terminal PH (pleckstrin homology) domain and a kinase domain, which are separated by a 39-amino-acid hinge region. Catalytically active Akt regulates the function of numerous substrates involved in cell survival, growth, proliferation, metabolism and protein synthesis. Akt is a crucial mediator of cell survival and its deactivation is implicated in various stress-induced pathological cell death and degenerative diseases.
-
Subcellular Localization
P31749: Cytoplasm; Nucleus; Cell membrane; Mitochondrion intermembrane space
P31751: Cytoplasm; Nucleus; Cell membrane; Peripheral membrane protein; Early endosome
Q9Y243: Nucleus; Cytoplasm; Membrane; Peripheral membrane protein -
Expression
Tissue_specificity: P31749: Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH) , ductal carcinoma in situ (DCIS) , invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages
P31751: Widely expressed. Expressed in myoblasts (PubMed:17565718)
Q9Y243: In adult tissues, it is highly expressed in brain, lung and kidney, but weakly in heart, testis and liver. In fetal tissues, it is highly expressed in heart, liver and brain and not at all in kidney -
Subunit
P31749: Interacts with BTBD10 (By similarity). Interacts with KCTD20 (By similarity). Interacts (via the C-terminus) with CCDC88A (via its C-terminus). Interacts with GRB10.
P31751: Interacts with BTBD10 (By similarity).
Q9Y243: Interacts (via PH domain) with TCL1A; this enhances AKT3 phosphorylation and activation. Interacts with TRAF6. -
Synonyms
AKT
Documentation
-
Data Sheet (263 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
User Guide for Antibodies (1077 KB)
References
[1]. Khalili M, et al. Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. Dig Dis Sci. 2018 Dec;63(12):3250-3252. [Content Brief]
[2]. Manola A, et al. Mastocytosis causing refractory hypotension after coronary angiography. Int J Cardiol. 2012 Apr 19;156(2):e43-4. [Content Brief]
[3]. Nitulescu GM, et al. The Akt pathway in oncology therapy and beyond (Review). Int J Oncol. 2018 Dec;53(6):2319-2331. [Content Brief]
[4]. Guerau-de-Arellano M, et al. Akt isoforms in the immune system. Front Immunol. 2022 Aug 23;13:990874. [Content Brief]
[5]. Hassan D, et al. AKT kinases as therapeutic targets. J Exp Clin Cancer Res. 2024 Nov 29;43(1):313. [Content Brief]
[6]. Wang Y, et al. Corrigendum to \"Mechanical stress protects against chondrocyte pyroptosis through TGF-β1-mediated activation of Smad2/3 and inhibition of the NF-κB signaling pathway in an osteoarthritis model\" [Biomed. Pharmacother., 2023 Mar:159:114216. [Content Brief]
Powered by Bioz
